Loading...
Prior to the approval of perioperative enfortumab vedotin plus the immune checkpoint inhibitor pembrolizumab (EVP), patients with muscle-invasive bladder cancer (MIBC) who were candidates for surgery but not for cisplatin-based neoadjuvant chemotherapy underwent radical cystectomy alone, with some subsequently offered adjuvant immune-checkpoint therapy. To study a different checkpoint inhibitor, durvalumab, in the perioperative setting, investigators conducted this industry-sponsored trial, randomizing almost 700 patients with MIBC undergoing cystectomy without neoadjuvant cisplatin to receive perioperative durvalumab plus enfortumab vedotin (DEV), DEV plus tremelimumab, or surgery alone.
Estimated event-free survival and o…